Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Epacadostat and Pembrolizumab in PD-1/PD-L1 Refractory Head and Neck Cancer
NCT03238638Phase 2Withdrawn
- Sponsor
- University of Chicago
- Start
- Sep 2018
- Primary completion
- Dec 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of epacadostat in head and neck squamous cell carcinoma (HNSCC), sponsored by University of Chicago. Planned start Sep 2018; status: withdrawn.
02
Drugs
epacadostat
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT03238638.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03238638.